A clinical-statistical study on COVID-19 infection and death status at the Alshifaa Healthcare Center/ Baghdad

Rasha Raheem; Mohammed Kadhom; Noor Albayati; Enas Alhashimie; Wathik Alrubayee; Israa Salman; Nany Hairunisa; Emad Yousif

doi:10.47419/bjbabs.v2i04.71

Authors

Rasha Raheem Alkarkh Health Directorate, Baghdad, Iraq
Mohammed Kadhom Department of Environment, College of Energy and Environmental Science, Alkarkh University of Science, Baghdad, Iraq
Noor Albayati Department of Science, College of Basic Education, University of Wasit, Azezia, Wasit, Iraq
Enas Z. Alhashimie Department of Chemistry, College of Science, Al-Mustansiriyah University, Baghdad, Iraq
Wathik A. Alrubayee Alshifaa center, The Medical City, Baghdad, Iraq
Israa Salman Department of Chemistry, College of Science, Al-Nahrain University, Baghdad, Iraq
Nany Hairunisa Department of Occupational Medicine, Faculty of Medicine, Trisakti University, Jakarta, Indonesia
Emad A. Yousif Department of Chemistry, College of Science, Alnahrain University, Baghdad, Iraq

DOI:

https://doi.org/10.47419/bjbabs.v2i04.71

Keywords:

ACE-2, transmission, SARS-CoV-2, transmissible diseases

Abstract

Background: COVID-19 is an ongoing disease that caused, and still causes, many challenges for humanity. In fact, COVID-19 death cases reached more than 4.5 million by the end of August 2021, although an improvement in the medical treatments and pharmaceutical protocols was obtained, and many vaccines were released.

Objective: To, statistically, analyze the data of COVID-19 patients at Alshifaa Healthcare Center (Baghdad, Iraq).

Methods: In this work, a statistical analysis was conducted on data included the total number, positive cases, and negative cases of people tested for COVID-19 at the Alshifaa Healthcare Center/Baghdad for the period 1 September – 31 December 2020. The number of people who got the test was 1080, where 424 were infected and the rest of them were not.

Results: The study showed that males’ infection and death cases were higher than females by more than double, despite the population ratios of the two genders being almost equal. Furthermore, as the age of patients is older, the chance of death is higher. Death cases were lower in December than the previous three months, which could be attributed to lower infection cases compared with the previous months.

Conclusions: We can conclude that the peak of infected ages was the same as the other countries. Hence, the number of checked children was low, while we have the peak around the 40s and 50s. Females’ death cases were much less than males, which could be attributed to the genetic influence and the higher responsibility that females showed than males to prevent the disease’s spreading.

Metrics

Metrics Loading ...

Downloads

Download data is not yet available.

References

A G Hadi et al. “A review on COVID-19: Origin, spread, symptoms, treatment, and prevention”. Biointerface Res Appl Chem 10 (2020), pp. 7234–7242. DOI: https://doi.org/10.33263/BRIAC106.72347242.

A G Hadi et al. “In COVID-19 time, how to protect myself and others? a review”. J Biomedika Kesehat 3(3) (2020), pp. 153–158. DOI: https://doi.org/10.18051/JBiomedKes.2020.v3.153-158.

G Forni and A Mantovani. “COVID-19 vaccines: where we stand and challenges ahead”. Cell Death Differ 28(2) (2021), pp. 626–639. DOI: https://doi.org/10.1038/s41418-020-00720-9.

G Ghazeeri, L Abdullah, and O Abbas. “Immunological differences in women compared with men: overview and contributing factors”. Am J Reprod Immunol 66(3) (2011), pp. 163–169. DOI: https://doi.org/10.1111/j.1600-0897.2011.01052.x.

I Y Elgendy and C J Pepine. “Why are women better protected from COVID-19: Clues for men? Sex and COVID-19”. Int J Cardiol 5(26) (2020), pp. 105–106. DOI: https://doi.org/10.1016/j.ijcard.2020.05.026.

Iraqi Ministry of Planning. URL: https://mop.gov.iq (visited on 2020).

Jian-Min Jin et al. “Gender differences in patients with COVID-19: Focus on severity and mortality”. Front Public Health 8 (2020), p. 152. DOI: https://doi.org/10.3389/fpubh.2020.00152.

L J Burchill et al. “Combination renin-angiotensin system blockade and angiotensin-converting enzyme 2 in experimental myocardial infarction: implications for future therapeutic directions”. Clin Sci (Lond) 123(11) (2012), pp. 649–658. DOI: https://doi.org/10.1042/CS20120162.

L S Y Wong et al. “Age-related differences in immunological responses to SARS-CoV-2”. J Allergy Clin Immunol Pract 8(10) (2020), pp. 3251–3258. DOI: https://doi.org/10.1016/j.jaip.2020.08.026.

M H Al-Mashhadani et al. “An overview: Coronaviruses in recent two decades”. Al-Nahrain J Sci 2021(5) (2021), pp. 13–16. DOI: 10.22401/ANJS.00.5.03.

M Hoffmann et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell 181(2) (2020), pp. 271–280. DOI: https://doi.org/10.1016/j.cell.2020.02.052.

M Tobaiqy et al. “Therapeutic management of COVID-19 patients: a systematic review”. Infect Prev Pract 2(3) (2020), p. 100061. DOI: https://doi.org/10.1016/j.infpip.2020.100061.

N Albayati et al. “Effect of COVID-19 on air quality and pollution in different countries”. J Transp Health 21 (2021), p. 101061. DOI: https://doi.org/10.1016/j.jth.2021.101061.

N G Davies et al. “Age-dependent effects in the transmission and control of COVID-19 epidemics”. Nat Med 26(8) (2020), pp. 1205–1211. DOI: https://doi.org/10.1038/s41591-020-0962-9.

R Alsayed et al. “An epidemiological characteristic of the COVID-19 among children”. Lett Appl NanoBioScience 9 (2020), pp. 1156–1164. DOI: https://doi.org/10.33263/LIANBS93.11561164.

R Alsayed et al. “Challenges facing Iraq to tackle the spread of COVID-19: An overview”. J Univ Anbar Pure Sci 14 (2020), pp. 22–27.

R Dijkman et al. “The dominance of human coronavirus OC43 and NL63 infections in infants”. J Clin Virol 53(2) (2012), pp. 135–139. DOI: https://doi.org/10.1016/j.jcv.2011.11.011.

R Raheem et al. “A clinical-statistical study on COVID-19 cases in Iraq: A case study”. Al-Nahrain J Sci 5(Special issue) (2021), pp. 6–12. DOI: https://doi.org/10.22401/ANJS.00.5.02.

S Bunyavanich, A Do, and A Vicencio. “Nasal gene expression of angiotensin-converting enzyme 2 in children and adults”. JAMA 323(23) (2020), pp. 2427–2429. DOI: https://doi.org/10.1001/jama.2020.8707.

S K Patel, E Velkoska, and L M Burrell. “Emerging markers in cardiovascular disease: Where does angiotensin-converting enzyme 2 fit in?” Clin Exp Pharmacol Physiol 40(8) (2013), pp. 551–559. DOI: https://doi.org/10.1111/1440-1681.12069.

S Marx et al. “RIG-I-induced innate antiviral immunity protects mice from lethal SARS-CoV-2 infection”. bioRxiv (2021). DOI: https://doi.org/10.1101/2021.08.06.455405.

U Ganbaatar and C Liu. “CRISPR-based COVID-19 testing: toward next-generation point-of-care diagnostics”. Front Cell Infect Microbiol 11 (2021), p. 663949. DOI: https://doi.org/10.3389/fcimb.2021.663949.

V B Patel et al. “Role of the ACE2/angiotensin 1-7 axis of the renin-angiotensin system in heart failure”. Cir Res 118(8) (2016), pp. 1313–1326. DOI: https://doi.org/10.1161/CIRCRESAHA.116.307708.

W H Al-Dahhan et al. “Iraq Faces the COVID-19 with Limited Health Capabilities and Major Medical Challenges”. Bionatura: Latin American Journal of Biotechnology and Life Sciences 5 (2020), pp. 1271–1274. DOI: https://doi.org/10.21931/RB/2020.05.03.19.

Y Yang et al. “The deadly coronaviruses: The 2003 SARS pandemic and the 2020 novel coronavirus epidemic in China”. J Autoimmun 109 (2020), p. 102434. DOI: https://doi.org/10.1016/j.jaut.2020.102434.